Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan Picks 5 COVID Vaccines for NIP Use from October
A Japanese health ministry panel on September 2 approved five COVID-19 vaccines for use under the national immunization program (NIP) in FY2026, with vaccinations to begin in October. Vaccines from the same five manufacturers as last year — Pfizer, Moderna…
To read the full story
Related Article
- Moderna Launches XFG-Updated mNEXSPIKE in Japan
September 24, 2026
- Takeda’s XFG-Targeted COVID Jab Approved in Japan
August 27, 2026
- Meiji Wins Japan Approval for NB.1.8.1-Adapted COVID Vaccine
August 27, 2026
- Japan Expects Flu Vaccine Supply of 51.9 Million Doses for 2026-27
August 27, 2026
- Moderna’s mNEXSPIKE Grabs Japan Approval for XFG Variant
August 20, 2026
- Pfizer, BioNTech Win Japan Nod for XFG-Adapted COVID Vaccines
August 18, 2026
- Takeda Files XFG-Adapted COVID Vaccine in Japan
June 29, 2026
- Japan Selects JN.1 Substrains for COVID Vaccines in 2026-2027 Season
May 27, 2026
- Japan Panel Approves 5 COVID Vaccines for NIP Use from October
September 9, 2025
- Japan Selects JN.1 Substrains for COVID Vaccines in 2025-2026 Season
May 30, 2025
REGULATORY
- Pharma Continues Reform Push at 2nd Public-Private Subgroup Meeting
October 13, 2026
- AbbVie’s TrenibotE Up for Review on Oct. 26, Aquipta on Agenda Too
October 13, 2026
- Japan Panel to Review Full Approval of Nipro’s Stemirac on October 15
October 13, 2026
- Japan Finalizes Medical Data Sharing Blueprint, Eyes 2027 Bill
October 13, 2026
- AlliedCel Takes Over Sakigake Designation for Junten Bio’s T-Cell Therapy
October 13, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…